Common ICD-10 Codes for Flow Cytometry Cancer Testing Local Coverage Determination Flow Cytometry ID L35032

Total Page:16

File Type:pdf, Size:1020Kb

Common ICD-10 Codes for Flow Cytometry Cancer Testing Local Coverage Determination Flow Cytometry ID L35032 Common ICD-10 Codes for Flow Cytometry Cancer Testing Local Coverage Determination Flow Cytometry ID L35032 Complete the 5-digit Lymphoma codes with a 5th digit Complete the 5-digit Leukemia/Myeloma codes with a 5th digit Unspecified site ..................................................................................................... 0 Not having achieved remission .......................................................................... 0 Lymph nodes of head, face and neck ............................................................. 1 In remission .............................................................................................................. 1 Intrathoracic lymph nodes .................................................................................. 2 In relapse .................................................................................................................. 2 Intra-abdominal lymph nodes ............................................................................. 3 Lymph nodes of axilla and upper limb .............................................................. 4 Multiple myeloma and malignant plasma cell neoplasms Lymph nodes of inguinal region and lower limb ........................................... 5 Multiple myeloma ........................................................................................... C90.0_ Intrapelvic lymph nodes ...................................................................................... 6 Plasma cell leukemia ..................................................................................... C90.1_ Spleen ....................................................................................................................... 7 Extramedullary plasmacytoma .................................................................... C90.2_ Lymph nodes of multiple sites ........................................................................... 8 Solitary plasmacytoma .................................................................................. C90.3_ Extranodal and solid organ sites ....................................................................... 9 Lymphoid leukemia Hodgkin lymphoma Acute lymphoblastic leukemia [ALL] ......................................................... C91.0_ Nodular lymphocyte predominant Hodgkin lymphoma ....................... C81.0_ Chronic lymphocytic leukemia of B-cell type ......................................... C91.1_ Nodular sclerosis Hodgkin lymphoma ..................................................... C81.1_ Prolymphocytic leukemia of B-cell type ................................................... C91.3_ Mixed cellularity Hodgkin lymphoma ........................................................ C81.2_ Hairy cell leukemia ......................................................................................... C91.4_ Lymphocyte depleted Hodgkin lymphoma ............................................. C81.3_ Adult T-cell lymphoma/leukemia (HTLV-1-associated) .......................... C91.5_ Lymphocyte-rich Hodgkin lymphoma ....................................................... C81.4_ Prolymphocytic leukemia of T-cell type ..................................................... C91.6_ Other Hodgkin lymphoma ........................................................................... C81.7_ Lymphoid leukemia, unspecified ............................................................... C91.9_ Hodgkin lymphoma, unspecified ............................................................... C81.9_ Mature B-cell leukemia Burkitt-type .......................................................... C91.A_ Other lymphoid leukemia ............................................................................. C91.Z_ Follicular lymphoma Follicular lymphoma grade I ........................................................................ C82.0_ Myeloid leukemia Follicular lymphoma grade II ....................................................................... C82.1_ Acute myeloblastic leukemia ...................................................................... C92.0_ Follicular lymphoma grade III, unspecified .............................................. C82.2_ Chronic myeloid leukemia, BCR/ABL-positive ........................................ C92.1_ Follicular lymphoma grade IIIa .................................................................... C82.3_ Atypical chronic myeloid leukemia, BCR/ABL-negative ...................... C92.2_ Follicular lymphoma grade IIIb ................................................................... C82.4_ Myeloid sarcoma ............................................................................................ C92.3_ Diffuse follicle center lymphoma................................................................ C82.5_ Acute promyelocytic leukemia ................................................................... C92.4_ Cutaneous follicle center lymphoma ........................................................ C82.6_ Acute myelomonocytic leukemia ............................................................... C92.5_ Other types of follicular lymphoma ........................................................... C82.8_ Acute myeloid leukemia with 11q23-abnormality ................................... C92.6_ Follicular lymphoma, unspecified .............................................................. C82.9_ Myeloid leukemia, unspecified ................................................................... C92.9_ Acute myeloid leukemia with multilineage dysplasia ........................... C92.A_ Non-follicular lymphoma Other myeloid leukemia ............................................................................... C92.Z_ Small cell B-cell lymphoma .......................................................................... C83.0_ Mantle cell lymphoma ................................................................................... C83.1_ Monocytic leukemia Diffuse large B-cell lymphoma .................................................................... C83.3_ Acute monoblastic/monocytic leukemia .................................................. C93.0_ Lymphoblastic (diffuse) lymphoma ............................................................ C83.5_ Chronic myelomonocytic leukemia ........................................................... C93.1_ Burkitt lymphoma ............................................................................................ C83.7_ Juvenile myelomonocytic leukemia .......................................................... C93.3_ Other non-follicular lymphoma .................................................................... C83.8_ Monocytic leukemia, unspecified .............................................................. C93.9_ Non-follicular (diffuse) lymphoma, unspecified ....................................... C83.9_ Other monocytic leukemia ........................................................................... C93.Z_ Mature T/NK-cell lymphomas Other leukemias of specified cell type Mycosis fungoides ......................................................................................... C84.0_ Acute erythroid leukemia ............................................................................. C94.0_ Sézary disease ................................................................................................ C84.1_ Acute megakaryoblastic leukemia ............................................................ C94.2_ Peripheral T-cell lymphoma, not classified .............................................. C84.4_ Mast cell leukemia ......................................................................................... C94.3_ Anaplastic large cell lymphoma, ALK-positive ........................................ C84.6_ Acute panmyelosis with myelofibrosis ..................................................... C94.4_ Anaplastic large cell lymphoma, ALK-negative ...................................... C84.7_ Myelodysplastic disease, not classified ................................................... C94.6 Mature T/NK-cell lymphomas, unspecified .............................................. C84.9_ Other specified leukemias ............................................................................ C94.8_ Cutaneous T-cell lymphoma, unspecified ............................................... C84.A_ Other mature T/NK-cell lymphomas .......................................................... C84.Z_ Leukemia of unspecified cell type Acute leukemia of unspecified cell type .................................................. C95.0_ Other specified and unspecified types of non-Hodgkin lymphoma Chronic leukemia of unspecified cell type .............................................. C95.1_ Unspecified B-cell lymphoma ..................................................................... C85.1_ Leukemia, unspecified ................................................................................... C95.9_ Mediastinal (thymic) large B-cell lymphoma ............................................ C85.2_ Other specified types of non-Hodgkin lymphoma ................................ C85.8_ Other and unspecified malignant neoplasms of lymphoid, Non-Hodgkin lymphoma, unspecified ....................................................... C85.9_ hematopoietic and related tissue Multifocal and multisystemic (disseminated) Langerhans-cell Malignant immunoproliferative diseases and certain other histiocytosis ....................................................................................................
Recommended publications
  • The Clinical Management of Chronic Myelomonocytic Leukemia Eric Padron, MD, Rami Komrokji, and Alan F
    The Clinical Management of Chronic Myelomonocytic Leukemia Eric Padron, MD, Rami Komrokji, and Alan F. List, MD Dr Padron is an assistant member, Dr Abstract: Chronic myelomonocytic leukemia (CMML) is an Komrokji is an associate member, and Dr aggressive malignancy characterized by peripheral monocytosis List is a senior member in the Department and ineffective hematopoiesis. It has been historically classified of Malignant Hematology at the H. Lee as a subtype of the myelodysplastic syndromes (MDSs) but was Moffitt Cancer Center & Research Institute in Tampa, Florida. recently demonstrated to be a distinct entity with a distinct natu- ral history. Nonetheless, clinical practice guidelines for CMML Address correspondence to: have been inferred from studies designed for MDSs. It is impera- Eric Padron, MD tive that clinicians understand which elements of MDS clinical Assistant Member practice are translatable to CMML, including which evidence has Malignant Hematology been generated from CMML-specific studies and which has not. H. Lee Moffitt Cancer Center & Research Institute This allows for an evidence-based approach to the treatment of 12902 Magnolia Drive CMML and identifies knowledge gaps in need of further study in Tampa, Florida 33612 a disease-specific manner. This review discusses the diagnosis, E-mail: [email protected] prognosis, and treatment of CMML, with the task of divorcing aspects of MDS practice that have not been demonstrated to be applicable to CMML and merging those that have been shown to be clinically similar. Introduction Chronic myelomonocytic leukemia (CMML) is a clonal hemato- logic malignancy characterized by absolute peripheral monocytosis, ineffective hematopoiesis, and an increased risk of transformation to acute myeloid leukemia.
    [Show full text]
  • Hematopoietic and Lymphoid Neoplasm Coding Manual
    Hematopoietic and Lymphoid Neoplasm Coding Manual Effective with Cases Diagnosed 1/1/2010 and Forward Published August 2021 Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER Margaret (Peggy) Adamo, BS, AAS, RHIT, CTR, NCI SEER Lois Dickie, CTR, NCI SEER Serban Negoita, MD, PhD, CTR, NCI SEER Suggested citation: Ruhl J, Adamo M, Dickie L., Negoita, S. (August 2021). Hematopoietic and Lymphoid Neoplasm Coding Manual. National Cancer Institute, Bethesda, MD, 2021. Hematopoietic and Lymphoid Neoplasm Coding Manual 1 In Appreciation NCI SEER gratefully acknowledges the dedicated work of Drs, Charles Platz and Graca Dores since the inception of the Hematopoietic project. They continue to provide support. We deeply appreciate their willingness to serve as advisors for the rules within this manual. The quality of this Hematopoietic project is directly related to their commitment. NCI SEER would also like to acknowledge the following individuals who provided input on the manual and/or the database. Their contributions are greatly appreciated. • Carolyn Callaghan, CTR (SEER Seattle Registry) • Tiffany Janes, CTR (SEER Seattle Registry) We would also like to give a special thanks to the following individuals at Information Management Services, Inc. (IMS) who provide us with document support and web development. • Suzanne Adams, BS, CTR • Ginger Carter, BA • Sean Brennan, BS • Paul Stephenson, BS • Jacob Tomlinson, BS Hematopoietic and Lymphoid Neoplasm Coding Manual 2 Dedication The Hematopoietic and Lymphoid Neoplasm Coding Manual (Heme manual) and the companion Hematopoietic and Lymphoid Neoplasm Database (Heme DB) are dedicated to the hard-working cancer registrars across the world who meticulously identify, abstract, and code cancer data.
    [Show full text]
  • Waldenstro¨M's Macroglobulinemia Is a Biological Syndrome Which May
    Correspondence 1637 cation,10 particularly in acute promyelocytic leukemia (APL), we References searched for genomic similarities. The few specific studies in existence on sequence analysis of the PML-RAR␣ gene show that the breakpoint within the involved gene (usually the PML locus) is variably situated, 1 Saglio G, Guerrasio A, Tassinari A, Ponzetto C, Zaccaria A, Testoni and that the corresponding fusion transcript should be aberrant. The P, Celso B, Rege Cambrin G, Serra A, Pegoraro L. Variability of the ␣ resulting PML-RAR proteins contained residues not homologous with molecular defects corresponding to the presence of a Philadelphia ␣ either PML or RAR . These reported atypical breaks were very similar chromosome in human hematologic malignancies. Blood 1988; to the one recorded in our case. A second original characteristic of 72: 1203–1208. the BCR break reported by us is that an intronic sequence derived 2 Chissoe SL, Bodenteich A, Wang YF, Wang YP, Burian D, Clifton from abl intron Ib was juxtaposed to bcr exon. This is another unpre- SW, Crabtree J, Freeman A, Iyer K, Jian L. Sequence and analysis cedented feature for a CML patient, although on rare occasions it has 10 of the human ABL gene, the BCR gene, and regions involved in been reported in AML patients. So, it may be speculated that in a the Philadelphia chromosomal translocation. Genomics 1995; 27: small proportion of the DNA breaks that occurs in leukemia, a cur- 67–82. rently unknown molecular mechanism could break the coding DNA. 3 Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, The resulting RNA remains in-frame coding an aberrant or, as in our Rege-Cambrin G, Mazza U, Gavosto F.
    [Show full text]
  • Lymphoproliferative Disorders
    Lymphoproliferative disorders Dr. Mansour Aljabry Definition Lymphoproliferative disorders Several clinical conditions in which lymphocytes are produced in excessive quantities ( Lymphocytosis) Lymphoma Malignant lymphoid mass involving the lymphoid tissues (± other tissues e.g : skin ,GIT ,CNS …) Lymphoid leukemia Malignant proliferation of lymphoid cells in Bone marrow and peripheral blood (± other tissues e.g : lymph nods ,spleen , skin ,GIT ,CNS …) Lymphoproliferative disorders Autoimmune Infection Malignant Lymphocytosis 1- Viral infection : •Infectious mononucleosis ,cytomegalovirus ,rubella, hepatitis, adenoviruses, varicella…. 2- Some bacterial infection: (Pertussis ,brucellosis …) 3-Immune : SLE , Allergic drug reactions 4- Other conditions:, splenectomy, dermatitis ,hyperthyroidism metastatic carcinoma….) 5- Chronic lymphocytic leukemia (CLL) 6-Other lymphomas: Mantle cell lymphoma ,Hodgkin lymphoma… Infectious mononucleosis An acute, infectious disease, caused by Epstein-Barr virus and characterized by • fever • swollen lymph nodes (painful) • Sore throat, • atypical lymphocyte • Affect young people ( usually) Malignant Lymphoproliferative Disorders ALL CLL Lymphomas MM naïve B-lymphocytes Plasma Lymphoid cells progenitor T-lymphocytes AML Myeloproliferative disorders Hematopoietic Myeloid Neutrophils stem cell progenitor Eosinophils Basophils Monocytes Platelets Red cells Malignant Lymphoproliferative disorders Immature Mature ALL Lymphoma Lymphoid leukemia CLL Hairy cell leukemia Non Hodgkin lymphoma Hodgkin lymphoma T- prolymphocytic
    [Show full text]
  • | Lymphoproliferative Disorders
    | Lymphoproliferative Hematology 438 teamwork disorders Color index: Red: Important Gray: notes Blue: extra Editing file Not malignant | definitions Lymphoproliferative disorders characters: -mature lymphocytes (no blasts), -lymphocytosis, Lymphoma -chronic. Lymphoid leukemia Several clinical conditions in Malignant proliferation of Malignant lymphoid mass which lymphocytes are lymphoid cells in Bone involving the lymphoid tissues produced in excessive marrow and peripheral blood (± other tissues ie; Extranodal quantities (Lymphocytosis) when the malignancy of lymphocytes reaches the lymphoma, by definition, involves sites other N.B: Lymphoproliferative disorders occur when the normal bone marrow or the peripheral blood we call it than lymph nodes, spleen, thymus and the mechanisms of control of proliferation of lymphocytes break lymphoid leukemia. pharyngeal lymphatic ring. e.g : skin down, resulting in autonomous, uncontrolled proliferation of lymphoid cells and typically leading to lymphocytosis and/or (± other tissues e.g : lymph ,GIT ,CNS) lymphadenopathy, and sometimes to involvement of extranodal sites, e.g. bone marrow. nodes ,spleen , skin ,GIT ,CNS) Autoimmune Infection Malignant Mostly virus Causes of lymphoproliferative disorder: These include (1) malignant—clonal in nature, resulting from the uncontrolled proliferation of a single transformed cell, e.g. lymphoma; (2) nonmalignant—polyclonal lymphoproliferative disorders may result from conditions including (a) infections—lymphocytosis is commonly caused by viral infections, e.g. Epsitein–Barr virus (EBV); lymphadenopathy is a common feature of a very wide variety of infections, (b) reactive—conditions such as systemic lupus erythematosus (SLE) and sarcoidosis frequently cause lymphadenopathy. | Lymphocytosis Blood film is very important, also Age is very important to expect the cause of lymphocytosis. Small lymphocytes: in non-infectious causes ●bacterial infection Some bacteria as ●Chronic lymphocytic ●Viral infection Pertussis ,brucellosis.
    [Show full text]
  • Leukemoid Reaction in a Patient with Acute Lymphoblastic Leukemia Following the Second Chemotherapy
    262JCEI / Yokuş et al. Leukemoid reaction in ALL 2013; 4 (2): 262-263 Journal of Clinical and Experimental Investigations doi: 10.5799/ahinjs.01.2013.02.0280 LETTER TO EDITOR Leukemoid reaction in a patient with acute lymphoblastic leukemia following the second chemotherapy Akut lenfoblastik lösemili hastada ikinci kemoterapi sonrası gelişen lökomoid reaksiyon Osman Yokuş1, Murat Albayrak2, Aynur Albayrak3, Habip Gedik4 To the Editor, to 50.000 cells/µL. The examined peripheral blood smear appeared as similar to the chronic phase of The occurrence of persistent neutrophilic leukocy- CML (fig.2). A cytogenetic examination of Philadel- tosis above 50,000 cells/µL for reasons other than phia chromosome [t(9:22] was found to be nega- leukemia is defined as leukemoid reaction. Chronic tive, therefore, CML was excluded in the patient. myelogenous leukemia (CML) and chronic neutro- Hydroxurea was initiated once a day. Leukocytosis philic leukemia (CNL) should be excluded, and un- recovered to normal range after one week (fig.3) derlying diseases or causes should be examined, and bone marrow examination revealed remission. in differential diagnosis. The most commonly ob- Cytogenetic analysis was normal and this leukocy- served causes of leukemoid reactions are severe tosis was determined as reactive leukemoid reac- infections, intoxications, malignancies, severe hem- tion. We aimed to report this case owing to the fact orrhage, or acute hemolysis [1]. J Clin Exp Invest that leukocytosis associated with G-CSF, which is 2013; 4 (2): 262-263 used to increase the leukocyte count during neutro- Rarely, leukemoid reaction can be seen in pa- penia, has been reported previously but it occurred tients with acute leukemia subsequent to chemo- after second chemotherapy without G-CSF [4].
    [Show full text]
  • Wikipedia: the Term Leukemoid Reaction Describes an Elevated White Blood
    Correspondence: I. Potasman, MD Leukemoid Reaction: Spectrum and Prognosis of 173 Adult Patients Infectious Diseases, ABSTRACT No. Bnai Zion Med. Ctr. 47 Golomb St., Haifa 31048. 39147 Israel Potasman, MD and Moti Grupper, MD Tel. 972-48359055 Fax. 972-48359755 Bnai Zion Med. Ctr., Haifa, Israel Email: [email protected] LR- CLINICAL and LABORATORY FEATURES CHRONIC DISEASES & CONDITIONS CAUSING LR METHODS WikipediA: The term leukemoid reaction describes an elevated white blood cell count, or leukocytosis, that is a physiological response to stress or infection (as Table 1: Leukemoid Reaction: Demographics, Major Clinical, and Laboratory features, and Table 2: Chronic & possible Instigating diseases Causing Leukemoid Reaction (n=173) The BZMC is a 411 bed university hospital located in Haifa, Israel. Mortality (n=173) Disease/Drug Occurrences (%) opposed to a primary blood malignancy, such as leukemia). Contains all basic departments except for neurosurgery, cardiovascular surgery and solid-tumor oncology. The respi- Parameter N (%) Alive Dead n Age (years, mean ±S.D.) 69.4 ±19.6 63.3±21.2 79.4±11.2 Background ratory intensive care unit inhabits six patients; additional respirators are in use in the 3 departments of medicine. History of Cardiovascular 86 (49.7%) Minimal-Maximal 21-97 21-97 28-97 ABSTRACT During an average year there are 29,508 hospitalizations of adults (>18 years) with ~150,000 hospitalization-days, Median 75 69 81 disease Diabetes Mellitus 46 (26.6%) and an average occupancy of 92%. Patients were eligible throughout hospital stay, and wherever they were admit- Chronic Lung disease 29 (16.8%) ted.
    [Show full text]
  • Management of Hepatic Burkitt Lymphoma in Children
    Gastroenterology & Hepatology International Journal ISSN: 2574-8009 Management of Hepatic Burkitt Lymphoma in Children Elhoudzi J* and Harif M Case Report Pediatric Hematology & Oncology Department, University Hospital Center, Morocco Volume 3 Issue 1 Medical school of Marrakesh, Cady Ayad University, Morocco Received Date: June 02, 2018 Published Date: June 15, 2018 *Corresponding author: Jamila Elhoudzi, Pediatric Hematology & Oncology Department, University Hospital Center, Morocco, Ibn Sina street, Ammerchich, 40000, Morocco, Tel: 00212661544256; Email: [email protected] . Abstract Hepatic Burkitt lymphoma is extremely rare in childhood and can be overlooked in differential diagnosis of liver masses. Patient: A8-year-old girl presented with a 1 month history of abdominal pain and weight loss and jaundice. Results: Physical examination revealed hepatomegaly and no palpable lymph node. Laboratory finding showed mild anemia (hemoglobin, 10,8 g/dL), elevated transaminase (ALT, 305 IU/L; ASAT,755 IU/L), elevated bilitubin (Bilirubin total, 179mg/L, Bilirubin direct, 143mg/l). Abdominal ultrasound shouwed a multiple hepatic lesions. Liver biopsy examination confirmed Burkitt's lymphoma. No metastasis was detected in the thoracic cavity, bone marrow, and spinal fluid. The patient was treated with the combination regimen of cyclophosphamide, doxorubicin, vincristine, prednisone and high dose methotrexate. Cytosine arabinoside and methotrexate were added for CNS prophylaxis by intrathecal installation. Serial follow-up ultrasound showed a marked decrease in the size of hepatic lesions but residual hilar lymph nodes at 2cm and the control showed stable size of lymph node after 28 months of chemotherapy. Conclusion: The clinical feature of primary hepaticlymphoma varies from no symptom to fulminant hepatic failure. There are no specific imaging criteria for diagnosing primary hepatic Burkitt’s lymphoma.
    [Show full text]
  • Predictive Significance of the Cut-Off Value of CD20 Expression in Patients with B-Cell Lymphoma
    1101-1107.qxd 25/8/2010 12:26 ÌÌ ™ÂÏ›‰·1101 ONCOLOGY REPORTS 24: 1101-1107, 2010 Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma MATEJA HORVAT1, VERONIKA KLOBOVES PREVODNIK2, JAKA LAVRENCAK2 and BARBARA JEZERSEK NOVAKOVIC3 1Bayer d.o.o., Bravnicarjeva 13; Departments of 2Cytopathology, 3Medical Oncology, Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia Received May 25, 2010; Accepted July 15, 2010 DOI: 10.3892/or_00000961 Abstract. The introduction of the anti-CD20 monoclonal 0.5667; 95%CI, 0.124 to 3.18, p=0.57]. Even though we have antibody, rituximab, into the treatment of patients with B-cell proved that patients with a CD20 expression level above the lymphomas has improved the overall response rate, as well as cut-off value treated with rituximab had a significantly longer the response duration and the overall survival of these patients. OS [hazard ratio (HR), 0.4573; 95%CI, 0.1364 to 0.9461, However, only a few studies have addressed the question of p=0.0383] than patients with a CD20 expression level below whether higher CD20 expression parallels with better treatment the cut-off value. Among our study population, 17.5% had a outcomes. The aim of this study was to assess the relationship CD20 expression level below the cut-off value. The highest between the level of CD20 expression and overall survival percentage (80%) of the patients with a CD20 expression (OS), disease-free survival (DFS) along with the overall level below the cut-off value belonged to the group of chronic response rate (ORR) in B-cell lymphoma patients.
    [Show full text]
  • Histologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years
    Case Report J Hematol. 2021;10(1):25-29 Histologic Transformation in an Untreated Waldenstrom’s Macroglobulinemia After 14 Years: Case Report and Review of the Literature Elizabeth B. Elimimiana, Nadeem Bilania, Maria J. Diacovoa, Skirmante Sirvaitisb, Chieh Lin Fua, c Abstract Introduction Waldenstrom’s macroglobulinemia (WM) is an indolent B-cell non- Waldenstrom’s macroglobulinemia (WM) is an indolent B-cell Hodgkin lymphoma characterized by lymphoplasmacytic histology non-Hodgkin lymphoma (NHL) representing 1-2% of all NHLs in the bone marrow with monoclonal IgM. Median survival can be in characterized by lymphoplasmacytic histology in the bone mar- excess of 10 years. The 5-year cumulative incidence of death is low row, with monoclonal IgM [1, 2]. WM was first described in at about 10%. One-third of all-cause specific mortality is due to the 1944 as having myeloma-like features, with proliferation of B lymphoma for which histologic transformation (HT) is rare. Here we cells causing increased serum IgM that can manifest as hyper- present a case of a 60-year-old man with longstanding untreated WM, viscosity syndrome. These include bleeding or thrombosis that presenting with minimally symptomatic transformation to diffuse can be associated with cryoglobulinemia, autoimmune hemo- large B-cell lymphoma (DLBCL), with an accompanying review of lytic anemia and neuropathy without corresponding osteolysis, the literature. Transformed WM, diagnosed greater than 5 years, has associated with lymphadenopathy and splenomegaly [2-4]. The a reported survival period of 8 - 9 months. This case highlights that MYD88 L265P mutation is detected in 90% of WM [1]. Median after a decade of continued stability in WM, not requiring treatment, age at diagnosis is 70; median survival can be in excess of 10 an acute change in laboratory data with minimally progressive IgM years; the 5-year cumulative incidence of death is low at about levels, in the absence of B symptoms and clinical findings, may be 10% [5].
    [Show full text]
  • Blood Cancers What to Expect and What Is New
    Blood Cancers What to Expect and What is New Raya Mawad, MD Swedish Cancer Institute Seattle, WA Activation of the Immune System What is Blood Cancer? Cancer of certain types of blood cells: -Myeloid Cells -Myelodysplastic Syndrome (MDS) -Acute Myeloid Leukemia (AML) -Chronic Myeloid Leukemia (CML) -Lymphoid Cells: -Lymphoma -Chronic Lymphoid Leukemia (CLL) -Acute Lymphoid Leukemia (ALL) Plasma cells: -MGUS -Multiple Myeloma Organs of the Immune System Anatomy of a Lymph Node Immune Defects Lymphoma B-cell DNA Breakage Inflammation proliferation Recombination Oncogene translocations Lymphomagenesis in Autoimmune Diseases Balancing Cell Production With Cell Death Normal Excessive Cell Insufficient Homeostasis Production Cell Death Cell Division Total Cell Numbers Cell Death Example ____ bcl-1 bcl-2 Courtesy of John C. Reed, MD, PhD Tumor Progression & Clonal Evolution Courtesy of T. Miller, MD Lymphoma, Leukemia & Myeloma Symptoms Swelling of lymph nodes (Lymphoma or lymphoid leukemia) -often, but not always painless Fever Drenching Night sweats Unexplained weight loss (> 10% baseline in a few months) Lack of energy Low blood counts or abnormally high white blood count Recurrent or Persistent infection (leukemia) Bone Pain Fractures or bone abnormalities on imaging Risk Factors Immunodeficiency disorders Autoimmune disorders Organ transplantation (immunosuppressed) Chemical or pesticide exposure (high level benzene, chemo) Radiation exposure (atomic bomb survivors) Bacteria or viruses (HIV, Hepatitis, EBV, HTLV-1, H. pylori) Lymphoma Staging
    [Show full text]
  • The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia
    From www.bloodjournal.org by guest on January 9, 2019. For personal use only. Review Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Daniel A. Arber,1 Attilio Orazi,2 Robert Hasserjian,3 J¨urgen Thiele,4 Michael J. Borowitz,5 Michelle M. Le Beau,6 Clara D. Bloomfield,7 Mario Cazzola,8 and James W. Vardiman9 1Department of Pathology, Stanford University, Stanford, CA; 2Department of Pathology, Weill Cornell Medical College, New York, NY; 3Department of Pathology, Massachusetts General Hospital, Boston, MA; 4Institute of Pathology, University of Cologne, Cologne, Germany; 5Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; 6Section of Hematology/Oncology, University of Chicago, Chicago, IL; 7Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH; 8Department of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and 9Department of Pathology, University of Chicago, Chicago, IL The World Health Organization (WHO) the prognostic relevance of entities cur- The 2016 edition represents a revision classification of tumors of the hemato- rently included in the WHO classification of the prior classification rather than poietic and lymphoid tissues was last and that also suggest new entities that an entirely new classification and at- updated in 2008. Since then, there have should be added. Therefore, there is a tempts to incorporate new clinical, prog- been numerous advances in the identifi- clear need for a revision to the current nostic, morphologic, immunophenotypic, cation of unique biomarkers associated classification.
    [Show full text]